Cargando…
Renal Cell Carcinoma Translational Biology, Personalized Medicine, and Novel Therapeutic Targets /
This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2012.
|
| Edición: | 1st ed. 2012. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4614-2400-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220115215039.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 120227s2012 xxu| s |||| 0|eng d | ||
| 020 | |a 9781461424000 |9 978-1-4614-2400-0 | ||
| 024 | 7 | |a 10.1007/978-1-4614-2400-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Renal Cell Carcinoma |h [electronic resource] : |b Translational Biology, Personalized Medicine, and Novel Therapeutic Targets / |c edited by Robert A. Figlin, W. Kimryn Rathmell, Brian I. Rini. |
| 250 | |a 1st ed. 2012. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Springer, |c 2012. | |
| 300 | |a XII, 328 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Preface -- The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies -- Molecular Biology of Clear Cell Renal Carcinoma -- HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment -- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC -- Molecular Characterization of Renal Cell Carcinoma -- Targeting The Vegf Pathway In Renal Cell Carcinoma -- Angiopoetins and Other Non-VEGF Antiangiogenic Targets In Advanced Renal Cell Carcinoma -- Towards Personalized Cancer Medicine -- Epigenetic Targeting and Histone Deacetylase Inhibition in RCC -- C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma -- Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies -- Carbonic Anhydrase IX: Its role as a biomarker, diagnostic, and therapeutic target in Renal Cell Carcinoma -- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials -- Mechanisms of Resistance to VEGF Directed Therapy and Implications for Future Trial Design -- Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma -- Index. | |
| 520 | |a This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy. Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Figlin, Robert A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Rathmell, W. Kimryn. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Rini, Brian I. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781461423997 |
| 776 | 0 | 8 | |i Printed edition: |z 9781489991393 |
| 776 | 0 | 8 | |i Printed edition: |z 9781461424017 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-4614-2400-0 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||